

NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®)


Myeloproliferative Neoplasms

Overall management of Myeloproliferative Neoplasms is described in the full NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms. Visit [NCCN.org](https://www.nccn.org) to view the complete library of NCCN Guidelines®.

Reproduced with permission from the NCCN Guidelines for Myeloproliferative Neoplasms V.1.2024. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to [NCCN.org](https://www.nccn.org). The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

TREATMENT FOR LOW-RISK POLYCYTHEMIA VERA^a



^a Special Considerations in the Treatment of PV and ET (MPN-I).

^b Cytoreductive therapy is not recommended as initial treatment.

^c Landolfi R, et al. N Engl J Med 2004;350:114-124.

^d Aspirin twice daily may be considered for patients with refractory symptoms (Dillinger JG, et al. Thromb Res 2012;129:91-94; Pascale S, et al. Blood 2012;119:3595-3603).

^e Hematocrit <45% is based on the data from the CYTO-PV study (Marchioli R, et al. N Engl J Med 2013;368:22-33). There may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized (eg, 42% for female patients and/or progressive symptoms).

^f Supportive Care for Patients with MPN (MPN-G).


^g Barbui T, et al. Leukemia 2018;32:1057-1069.

^h See IWG-MRT (MPN-B), ICC, and WHO diagnostic criteria for post-PV MF (MPN-C).

ⁱ Peginterferon alfa-2a is an option for younger patients or in pregnant patients in need of cytoreductive therapy.

**Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

TREATMENT FOR HIGH-RISK POLYCYTHEMIA VERA^a



^a Special Considerations in the Treatment of PV and ET (MPN-I).

^c Landolfi R, et al. N Engl J Med 2004;350:114-124.

^d Aspirin twice daily may be considered for patients with refractory symptoms (Dillinger JG, et al. Thromb Res 2012;129:91-94; Pascale S, et al. Blood 2012;119:3595-3603).

^e Hematocrit <45% is based on the data from the CYTO-PV study (Marchioli R, et al. N Engl J Med 2013;368:22-33). There may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized (eg, 42% for female patients and/or progressive symptoms).

^f Supportive Care for Patients with MPN (MPN-G).

^g Barbui T, et al. Leukemia 2018;32:1057-1069.

^h See IWG-MRT (MPN-B), ICC, and WHO diagnostic criteria for post-PV MF (MPN-C).

ⁱ Peginterferon alfa-2a is an option for younger patients or in pregnant patients in need of cytoreductive therapy.

^j Response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the 2013 IWG-MRT and ELN Response Criteria for PV (PV-A). Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

^k While normalization of blood counts after initiation of treatment is usually a goal in clinical practice, it is not associated with long-term clinical benefit and there are no evidence-based data to recommend a target white blood cell (WBC) or platelet count for patients receiving cytoreductive therapy. In selected patients with a severe thrombotic event or other disease-related symptoms, normalization of blood counts might be an essential goal of treatment.

^l Definition of intolerance/resistance to hydroxyurea (MPN-J).

^m Ruxolitinib is FDA approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. Ruxolitinib may have activity after inadequate response or loss of response to other agents besides hydroxyurea. See Discussion.

**Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

Category 1	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Preferred intervention	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
Useful in certain circumstances	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 1.2024, 12/21/23 © 2023 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

CAT-1

The National Comprehensive Cancer Network® (NCCN®) appreciates that supporting companies recognize NCCN's need for autonomy in the development of the content of NCCN resources. All NCCN Guidelines are produced completely independently. NCCN Guidelines are not intended to promote any specific therapeutic modality.

The distribution of this flashcard is supported by PharmaEssentia USA Corporation.